乳腺癌中ezrin和VEGF的表达及其临床意义  

Expression of ezrin and VEGF proteins in breast cancer and their clinical significance

作　　者：李文广[1] 张燕妮[1] 颜海[1] 凌黎[1] 管同郁[1] 叶涛[1] 李京微 姜海英[1] 李艳芳[1] 

机构地区：[1]徐州市第三人民医院暨徐州市肿瘤医院,江苏徐州221005

出　　处：《现代肿瘤医学》2009年第6期1063-1065,共3页Journal of Modern Oncology

基　　金：2006年徐州市科技计划项目(编号:XZ2006240)

摘　　要：目的:探讨ezrin和VEGF在乳腺癌组织中的表达及其与淋巴细结转移,临床分期以及预后之间的关系。方法:应用免疫组化S-P方法,检测63例乳腺癌组织ezrin和VEGF的表达。结果:63例乳腺癌中ezrin和VEGF表达率分别为55.56%(35/63)和65.08%(41/63),ezrin和VEGF在乳腺癌中的表达和淋巴结转移,临床分期呈正相关而和无病生存时间呈负相关(P<0.05)。但与年龄、肿块大小以及月经情况无相关性(P>0.05)。结论:检测ezrin和VEGF有助于判断乳腺癌的转移潜能,ezrin有可能成为判断肿瘤预后的新指标。Objective：To explore the expression and clinical significance of ezrin and VEGF in breast cancer,and to evaluate its relationship with lymph node metastasis, clinical stage and prognosis. Methods： Immunohistochemical staining（ S - P） was used to detect the expression of ezrin and VEGF in 63 cases of breast cancer samples. Results： In 63 cases of breast cancer,the positive expression rates of ezrin and VEGF were 55.56% and 65.08% ,respectively. The expression of ezrin and VEGF were positively correlated with lymph node metastasis, clinical stage and negatively correlated with DFS （ P 〈 0.05 ）, but not related to tumor size, age and menopausal status （ P 〉 0.05 ）. Conclusion： Ezrin and VEGF expression may have significant prognostic value for assessing the degree of malignancy and potential lymph node metastasis probability of breast cancer.

关 键 词：ezirn VEGF 乳腺癌 免疫组化 预后 

分 类 号：R737.9[医药卫生—肿瘤]